Related references
Note: Only part of the references are listed.Biology of interactions: Antiepidermal growth factor receptor agents
Paul M. Harari et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
J. Randolph Hecht et al.
CANCER (2007)
Overexpression of epidermal growth factor type-l receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Stefania Bellone et al.
GYNECOLOGIC ONCOLOGY (2007)
Antibodies to the epidermal growth factor receptor in non-small cell lung cancer: Current status of matuzumab and panitumumab
Mark A. Socinski
CLINICAL CANCER RESEARCH (2007)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Andrea Sartore-Bianchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor -: Positive premenopausal breast cancer
Jennifer M. Giltnane et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E. Pelloski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Her signaling in pancreatic cancer
Barbara Burtness
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: A case report
James Heun et al.
CLINICAL COLORECTAL CANCER (2007)
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies
M. V. Seiden et al.
GYNECOLOGIC ONCOLOGY (2007)
The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: A call for standardized methods for immunohistochemical evaluation
David Cohen et al.
CLINICAL GENITOURINARY CANCER (2007)
FDA drug approval summary: Panitumumab (Vectibix (TM))
Ruthann M. Giusti et al.
ONCOLOGIST (2007)
Panitumumab in colon cancer: a review and summary of ongoing trials
Zev Wainberg et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Cetuximab in the treatment of head and neck cancer
Jacques Bernier
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Integration of EGFR inhibitors with radiochemotherapy
Mukesh K. Nyati et al.
NATURE REVIEWS CANCER (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer
John V. Heymach et al.
CLINICAL CANCER RESEARCH (2006)
The evolving role of cetuximab in non-small cell lung cancer
Rogerio C. Lilenbaum
CLINICAL CANCER RESEARCH (2006)
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
C. Kollmannsberger et al.
ANNALS OF ONCOLOGY (2006)
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
U Graeven et al.
BRITISH JOURNAL OF CANCER (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Current status of cetuximab for the treatment of patients with solid tumors
DA Frieze et al.
ANNALS OF PHARMACOTHERAPY (2006)
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer
J Edwards et al.
CLINICAL CANCER RESEARCH (2006)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
Christine H. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme
RJ Raizer
JOURNAL OF NEURO-ONCOLOGY (2005)
Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?
AP Dei Tos et al.
EUROPEAN JOURNAL OF CANCER (2005)
Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report
P Nygren et al.
ACTA ONCOLOGICA (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
M Younes
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy
R Hitt et al.
EUROPEAN JOURNAL OF CANCER (2005)
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
T Crombet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
EK Rowinsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies
M Scartozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections
D Atkins et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor
U Vanhoefer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer
T Crombet et al.
JOURNAL OF IMMUNOTHERAPY (2003)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Share Paper
